bezafibrate has been researched along with Bone Marrow Failure Syndromes, Congenital in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Asahina, N; Egawa, K; Hayashi, H; Ishige, M; Isoe, T; Kawakami, S; Kobayashi, K; Kuzume, K; Miyakoshi, T; Nakamagoe, K; Oba, K; Ochi, F; Sameshima, K; Sato, N; Shiraishi, H; Tamaoka, A; Watanabe, A; Watanabe, K; Yamada, K; Yamaguchi, S; Yokoshiki, S | 1 |
| Andersen, KG; Gregersen, N; Hargreaves, IP; Heaton, R; Lund, M; Olsen, RKJ | 1 |
| Andersen, G; Laforêt, P; Madsen, KL; Preisler, N; Vissing, J; Ørngreen, MC | 1 |
| Bastin, J; Bonnefont, JP; Bresson, JL; Djouadi, F | 1 |
| Laforét, P; Vissing, J; Ørngreen, MC | 1 |
| Ding, Y; Li, X; Liu, Y; Ma, Y; Song, J; Wang, Q; Yang, Y | 1 |
1 trial(s) available for bezafibrate and Bone Marrow Failure Syndromes, Congenital
| Article | Year |
|---|---|
Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Aged; Bezafibrate; Carnitine O-Palmitoyltransferase; Clinical Protocols; Congenital Bone Marrow Failure Syndromes; Cross-Over Studies; Fatty Acids; Female; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Muscular Diseases; Treatment Outcome; Young Adult | 2014 |
5 other study(ies) available for bezafibrate and Bone Marrow Failure Syndromes, Congenital
| Article | Year |
|---|---|
Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adult; Bezafibrate; Child; Congenital Bone Marrow Failure Syndromes; Female; Humans; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases | 2021 |
Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Topics: Bezafibrate; Congenital Bone Marrow Failure Syndromes; Energy Metabolism; Fibroblasts; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Mitochondria; Mitochondrial Diseases; Muscular Diseases; Oxidative Stress; Peroxisome Proliferator-Activated Receptors | 2021 |
Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Carnitine O-Palmitoyltransferase; Congenital Bone Marrow Failure Syndromes; Fatty Acids; Heart Rate; Humans; Lipid Metabolism, Inborn Errors; Lipolysis; Metabolism, Inborn Errors; Mitochondrial Diseases; Muscular Diseases; Oxidation-Reduction; Treatment Outcome | 2015 |
No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Carnitine O-Palmitoyltransferase; Congenital Bone Marrow Failure Syndromes; Fatty Acids; Humans; Lipid Metabolism, Inborn Errors; Lipolysis; Metabolism, Inborn Errors; Mitochondrial Diseases; Muscular Diseases | 2015 |
Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Acyl-CoA Dehydrogenases; Amniotic Fluid; Ascorbic Acid; Asian People; Bezafibrate; Carnitine; Case-Control Studies; China; Chromatography, Liquid; Congenital Bone Marrow Failure Syndromes; DNA, Complementary; Exons; Female; Genetic Testing; Heterozygote; Humans; Infant; Infant Formula; Infant, Newborn; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases; Mutation, Missense; Neonatal Screening; Prenatal Diagnosis; Sequence Alignment; Sequence Analysis, DNA; Tandem Mass Spectrometry; Treatment Outcome; Triglycerides; Vitamin B Complex | 2015 |